Events

Videos

Podcasts

Articles

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ruxolitinib's Role in Treating Myelofibrosis

Myelofibrosis: Diagnosis and Risk Stratification

Optimizing the Use of Ruxolitinib for Polycythemia Vera

Ruxolitinib's Role in Treating Polycythemia Vera

Selecting Appropriate Therapy at Progression of PV

Polycythemia Vera: Controlling HCT and WBC

Determining Inadequate Control or Intolerance in PV

Polycythemia Vera: Considerations for Frontline Therapy

Polycythemia Vera: Making a Diagnosis

Suspecting Polycythemia Vera: Challenges in Diagnosis

MPNs: Differentiating Between ET, PV, and MF

An Overview of Myeloproliferative Neoplasms

David S. Snyder, MD, details mutations and discusses investigational treatments within the field of myeloproliferative neoplasms.

Expert Details Developments in MPN Paradigm

Future Direction for Polycythemia Vera

PV: Treatment With Ruxolitinib

Rationale for JAK Inhibition in PV

PV: Clinical Use of Hydroxyurea

Clinical Control of Polycythemia Vera

Initial Approach to PV Treatment

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.

Dr. Snyder on Ruxolitinib in Patients With Myelofibrosis

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.